| |
|
|
| |
|
|
| |
|
Jeffrey Stuart Dome, MD, PhD
|
|
 |
Center of Excellence, Departments, and Programs
The Center for Cancer and Blood Disorders
Division Chief, Oncology
Solid Tumor Program
Children’s Research Institute (CRI)
Center for Cancer and Immunology Research
View CRI Profile for Jeffrey Stuart Dome
Specialties: Renal Tumors
|
|
| Board Certifications |
American Board of Pediatrics/Hematology-Oncology
|
National Provider Identifier
 |
1902809197 |
|
| Practice Locations |
Children's National Medical Center - Main Hospital
111 Michigan Avenue, NW
Washington, DC
Phone: 202-476-5000
 
|
|
| Biography |
Jeffrey Stuart Dome, MD, is chief of the Division of Oncology.
Dr. Dome specializes in pediatric solid tumors, with an emphasis on Wilms tumors and other pediatric kidney tumors. As chair of the Renal Tumor Committee for the Children's Oncology Group (COG), Dr. Dome oversees clinical trials for Wilms tumors and other childhood kidney cancers in more than 200 children's hospitals. He has authored more than 30 articles and textbook chapters on pediatric kidney tumors.
Dr. Dome lives in Maryland with his wife, son, and daughter.
|
|
| Education |
| Type | School | Location | Degree | Field of Study | Years | | Undergraduate Education | University of Pennsylvania | Philadelphia, PA | Bachelor of Arts | | 1983 -1987 | | Medical School | University of Pennsylvania School of Medicine | Philadelphia, PA | Doctor of Medicine | | 1987 -1991 |
|
|
| Training |
| Type | Institution | Location | Position | Specialty | Years | | Internship Program | Yale New Haven Hospital | New Haven, CT | Intern | | 1991 - 1992 | | Residency Program | Yale New Haven Hospital | New Haven, CT | Resident | | 1992 - 1994 | | Fellowship Program | Johns Hopkins Hospital | Baltimore, MD | Fellow | | 1994 - 1997 |
|
|
| National and International Recognition |
| Award | Institution | Event | Year | | Giulio D'Angio Award | | International Conference on the Molecular and Clinical Genetics of Childhood Renal Tumors | 1999 | | Young Investigator Award | American Society of Clinical Oncology | | 1997 |
|
|
| Affiliations and Memberships |
| Title | Institution | Committee / Section | Years | | Chairman | Children's Oncology Group | Renal Tumor Committee | 2006 - 2009 | | Chairman | Children's Oncology Group | Renal Tumor Biology Committee | 2002 - 2006 |
|
|
| Research |
| Title | Study Name | Institution | Years | | Principal Investigator | A phase II study of topotecan for recurrent Wilms tumor | Glaxo Smith Kline | 2005 - 2007 | | | Principal Investigator | Telomerase as a prognostic indicator for Wilms tumor | National Cancer Institute | 2000 - 2005 | | | Read more about the research interests of Jeffrey Stuart Dome |
|
|
| Publications |
Journal Article, Davidoff AM, Giel DW, Jones DP, Jenkins JJ, Krasin MJ, Hoffer FA, Williams MA, and Dome JS (2008), The feasibility and outcome of nephron-sparing surgery for children with bilateral Wilms tumor: The St. Jude Children’s Research Hospital Experience: 1999-2006, Cancer, 112, 2060-2070.
Journal Article, Metzger MM, Stewart CF, Freeman BB, Billups CA, Hoffer FA, Wu J, Coppes MJ, Grant R, Chintagumpala M, Mullen EA, Alvarado C, Daw NC, and Dome JS (2007), Topotecan is active against Wilms tumor: Results of a multi-institutional phase II study, Journal of Clinical Oncology, 25, 3130-3136.
Journal Article, Tabori U and Dome JS (2007), Telomere biology of pediatric cancer, Cancer Investigation, 25, 197-208.
Journal Article, Dome JS, Cotton CA, Perlman EJ, Breslow NE, Kalapurakal JA, Ritchey ML, Grundy PE, Malogolowkin M, Beckwith JB, Shamberger RC, Haase GM, Coppes MJ, Coccia P, Kletzel M, Macklis R, and Green DM (2006), Treatment of Anaplastic Histology Wilms Tumor: Results from the Fifth National Wilms Tumor Study, Journal of Clinical Oncology, 20, 2352-2358.
Journal Article, Tomlinson GE, Breslow NE, Dome J, Guthrie KA, Norkool P, Li S, Thomas P, Beckwith JB, D’Angio GJ, and Green DM (2005), Age at diagnosis as a prognostic factor for rhabdoid tumor of the kidney: A report from the National Wilms Tumor Study Group, Journal of Clinical Oncology, 23, 7641-7645.
Journal Article, Dome JS, Bockhold CA, Li SM, Baker SD, Green, DM, Perlman EJ, Hill DA, and Breslow NE (2005), High telomerase RNA expression is an adverse prognostic factor for favorable histology Wilms tumor, Journal of Clinical Oncology, 23, 9138-9145.
Journal Article, Bakkenist CJ, Drissi R, Wu J, Kastan MB, and Dome JS (2004), Disappearance of the Telomere dysfunction-induced stress response in fully senescent cells, Cancer Research, 64, 3748-3752.
Journal Article, Sanders RP, Drissi R, Billups CA, Daw NC, Valentine MB, and Dome JS (2004), Telomerase expression predicts unfavorable outcome in osteosarcoma, Journal of Clinical Oncology, 22, 3790-3797.
Journal Article, Dome JS and Coppes, MJ (2002), Recent advances in Wilms tumor genetics, Current Opinion in Pediatrics, 14, 5-11.
Journal Article, Dome JS, Liu T, Krasin M, Lott L, Shearer P, Daw N, Billups CA, and Wilimas JA (2002), Improved survival for patients with recurrent Wilms tumor, Journal of Pediatric Hematology Oncology, 24, 192-198.
For a more comprehensive list of publications for Jeffrey Dome, MD, PhD view the National Library of Medicine’s PubMed online database |
|
|
|
|
|
|
